Slide 1: Corporate Presentation January 2026
DBV TECHNOLOGIES © 2024, DBV Technologies. All rights reserved Corporate Presentation I January 2026 Euronext Paris: DBV |ICorporate DBV Technologies Nasdaq: DBVT Overview
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward looking statements including, but not limited to, statements concerning DBV’s financial condition and forecast of its cash runway; the exercise of warrants following the disclosure of VITESSE positive topline results; the exercise by investors
Slide 3: Our Mission is to Develop Novel Treatments for Pediatric Food Allergy
Our Mission is to Develop Novel Treatments for Pediatric Food Allergy Global, late-stage, biopharmaceutical company Committed to transforming lives of children & families living with the daily burden of food allergy Pioneered VIASKIN® patch technology DBV’s novel approach to epicutaneous immunothera
Slide 4: Regulatory Overview (US)
Regulatory Overview (US) Two Distinct Opportunities Clear Regulatory Pathway Anticipated Clinical & for TwoVIASKIN® Peanut Patch Distinct Opportunities for Both Programs Regulatory Milestones One BLA in 4-7 YO The successful VITESSE - BLA submission anticipated Phase 3 study, will support for 1H264
Slide 5: Significant Market Opportunity for VIASKIN Peanut Patch
Significant Market Opportunity for VIASKIN® Peanut Patch ~670K Children Aged 1-7 Years Have Peanut Allergy in US1-3 1-3 years old 4-7 years old 280,000 Toddlers1-3 390,000 Children1-3 1. CDC National Population Projections 2014-2060 https://wonder.cdc.gov/population-projections-2014-2060.html 2. Gup
Slide 6: Square & Circular VIASKIN Peanut Patches Are Separate Product Candidates
Square & Circular VIASKIN® Peanut Patches Are Separate Product Candidates – Two Distinct Opportunities in US Independent Clinical & Regulatory Paths for VIASKIN® Peanut Patch in Toddlers 1–3 YO & Children 4–7 YO Square Patch Circular Patch 1-3 YO 4-7 YO Target Age Overlay Size 34 mm/side 44 mm diame
Slide 7: Anticipated Near-Term Milestones
Anticipated Near-Term Milestones Upcoming Milestones & Catalysts Anticipated in 2026 CHILDREN (4-7 years) BLA submission for 4-7 YO anticipated in 1H 20261 Eligible for Priority Review (~8 Months Total Vs ~12 months Total with Standard Review) TODDLERS (1-3 years) Completion of enrollment of COMFORT
Slide 8: EMA Provided Guidance for Marketing Authorization Application (MAA)
EMA Provided Guidance for Marketing Authorization Application (MAA) for the Circular VIASKIN® Peanut Patch in 1-7 Year Olds The unmet need for peanut allergy in Europe is significant: ▪ Estimated that 615,000 children ages 1 – 7 YO in the EU have peanut allergy1 ▪ Incidence of new diagnosis of ~81,0
Slide 9: U.S. Commercial Opportunity VIASKIN Peanut Patch
U.S. COMMERCIAL OPPORTUNITY VIASKIN® PEANUT PATCH NYSE American: PHGE
Slide 10: The Peanut Allergy Epidemic
” The Peanut Allergy Epidemic OFTEN A LIFELONG BURDEN STARTING AT AN EARLY AGE 92% 41% of peanut allergy cases have an accidental exposure emerge by age of 72; ~80% within 3 years of diagnosis4 “…mass explosion are lifelong3 of food allergy…” Reactions unpredictable and can be life-threatening - Dr.
Slide 11: Current Treatment Options Are Often Not Ideal for Patients & Their Families
Current Treatment Options Are Often Not Ideal for Patients & Their Families1-4 Oral Immunotherapy (Approvedⱡ & Non-Proprietary) Omalizumab (anti-IgE Monoclonal Antibody)ⱡⱡ Complex dose escalation schedule, requiring multiple Fear of injection: visits to an allergist’s office that can each last >1 ho
Slide 12: VIASKIN Peanut Patch – A Potential Treatment for Peanut Allergy
VIASKIN® Peanut Patch – A Potential Treatment for Peanut Allergy That Can Be Easily Incorporated into the Busy Lives of Families Potential Benefits of Epicutaneous Immunotherapy with VIASKIN® Peanut Patch Applied at home, once a day onto child’s back No treatment escalation requiring frequent doctor
Slide 13: Peanut Allergy Market Dynamics: Patients, Prescribers, Payers
PEANUT ALLERGY MARKET DYNAMICS The Patients The Prescribers The Payers 670K Children 4,500 Allergists 50 Payers ages 1 to 7 years old 1,2 in the US1,2 cover +85% of lives DBV will leverage its strong 50 to 70-person specialty sales force 8 – 10 account managers can build relationships with Advocacy
Slide 14: Peanut Allergy Market Dynamics: Pediatricians and Parents
PEANUT ALLERGY MARKET DYNAMICS Pediatricians Parents 60K 7.2M Pediatricians Millennials in the US born between 1981 and 1996 PEDs overwhelmingly follow the AAP guidance to Most millennials turn to digital spaces for health refer families to an Allergist for immunotherapy information and advice • DBV
Slide 15: External Engagements: HCP Interactions Designed to Activate, Learn, and Inform
External Engagements: HCP Interactions Designed to Activate, Learn, and Inform HCP engagement, driven by the MSL team, is aimed at educating and gathering expert insights through 1:1 meetings, congress activities, and advisory boards 2026 Advisory Boards Insights gathering across geographies and spe
Slide 16: VIASKIN Peanut is a breakthrough patch with the potential to revolutionize treatment
VIASKIN Peanut is a breakthrough patch with the potential to revolutionize treatment in a large market with significant unmet need DIFFERENTIATION: Ability to address peanut allergy with a non-invasive patch that creates sustainable differentiation SIZEABLE MARKET AT LAUNCH: Launch momentum in 1-7 Y
Slide 17: The Science of Epicutaneous Immunotherapy (EPIT)
THE SCIENCE OF EPICUTANEOUS IMMUNOTHERAPY (EPIT) 17
Slide 18: EPIT Aims to Re-educate the Immune System Thus Suppressing the Allergic Response
Epicutaneous Immunotherapy (EPIT) Aims to Re-educate the Immune System Thus Suppressing the Allergic Response1-7 Regulatory T Cells act on the immune system to Antigen Presenting Cells suppress the allergic response EPIT delivers allergen capture allergen and induce to the skin unique Regulatory T C
Slide 19: VIASKIN Patch: Our Innovative Approach to Epicutaneous Immunotherapy
VIASKIN® Patch: Our Innovative Approach to Epicutaneous Immunotherapy1-3 A Novel Drug-Device Combination for Delivering Allergen Immunotherapy Adhesive Overlay PET Titanium Backing Condensation Chamber Allergen Adhesive Crown Condensation Chamber Allergen Solubilization formed by adhesive crown, all
Slide 20: VIASKIN Patch Uses Minimal Amounts of Allergen to Induce Desensitization
VIASKIN® Patch Uses Minimal Amounts of Allergen to Induce Desensitization1-3 1/1000th of a peanut is applied daily to the skin Allergen 3 years of treatment with VIASKIN® Peanut patch (250 µg) is equivalent in exposure VIASKIN® Patch amount to 1 peanut kernel Solubilized allergen is captured by spec
Slide 21: Desensitization is Measured by Increases in Eliciting Dose (ED)
Desensitization is Measured by Increases Decrease in Reaction Risk with Increased in Eliciting Dose (ED) ED Following Allergen Immunotherapy ED = the amount of allergen that induces allergic symptoms1: SKIN: erythematous rash, scratching, hives, lip or face swelling UPPER RESPIRATORY: sneezing/itchi
Slide 22: VIASKIN Peanut Patch Program in Children Ages 4-7 Years Old
VIASKIN® Peanut Patch Program in Children Ages 4-7 Years Old DBV Technologies | Corporate Overview
Slide 23: VITESSE Study Design
VITESSE Study Design • 654 subjects ages 4-7 YO (vs target enrollment of 6001) • Largest immunotherapy clinical trial for this patient population2 • DBV’s CIRCULAR VIASKIN® Peanut patch (containing 250 mg peanut protein extract) Global Phase 3 Trial Randomized, double-blind, placebo-controlled VIASK
Slide 24: The VITESSE Phase 3 Study Met the Primary Endpoint
The VITESSE Phase 3 Study Met the Primary Endpoint † Treatment Responders P<0.001** Δ= 31.8% (95% CI: 24.5, 39.0) The treatment effect observed in VITESSE (31.8%) is consistent with the treatment effect observed in the Phase 3 EPITOPE (33.4%) study in 1-3-year-olds N=436 N=218 95% CI Lower Bound of
Slide 25: VITESSE Safety Summary
VITESSE Safety Summary Safety results consistent with prior trials, which now encompass over 1,600 children and more than 1.1 million patch applications The most common Treatment Emergent Adverse Events (TEAEs) observed during VITESSE were mild-to-moderate local skin reactions at the patch applicati
Slide 26: VIASKIN Peanut Patch Program in Toddlers (Ages 1–3 Years Old)
VIASKIN® Peanut Patch Program in Toddlers (Ages 1–3-Years Old) DBV Technologies | Corporate Overview
Slide 27: Phase 3 EPITOPE: VIASKIN Peanut Patch in Toddlers 1-3 Years of Age
Phase 3 EPITOPE: VIASKIN® Peanut Patch in Toddlers 1-3 Years of Age Study Design for EPITOPE Pivotal Global Study1 & Open-Label Extension (OLE) to EPITOPE Study2 EPITOPE Open-Label Extension (“EPOPEX”) High % of subjects opted to stay on VP250 VP250 VP250 after Year 1 EPITOPE through 36 Months3,4 n=
Slide 28: Positive Month 12 Results from Phase 3 EPITOPE Study
Positive Month 12 Results from Phase 3 EPITOPE Study with Primary Endpoint Met & with a Favorable Safety & Tolerability Profile PRIMARY ENDPOINT MET 1-3 OTHER ENDPOINTS 1-3 SAFETY 1-3 67.0% of participants 64.2% of participants reached an ED VP250 was well-tolerated, on VP250 were of ≥1000 mg (equiv
Slide 29: EPITOPE Open-Label Extension Shows Continued Improvement Through 36 MO
EPITOPE Open-Label Extension Shows Continued Improvement in Treatment Response in Toddlers Through 36 MO1-4 • 175 subjects entered OLE study (out of 244 randomized to receive VP250 in EPITOPE1) • 166 subjects (95%) of those in the OLE underwent DBPCFC at Month 24 • 149 subjects (85%) underwent DBPCF
Slide 30: Data from EPITOPE Open-Label Extension Show Continued Improvement
Data from EPITOPE Open-Label Extension Show Continued Improvement in Treatment Response in Toddlers Through 36 MO1-4 Eliciting Dose ≥2000 mg Completed Food Challenge* Without (Equivalent of 6-8 peanuts) Meeting Stopping Criteria *3444 mg cumulative dose consumed 100 100 Percentage of Participants Pe
Slide 31: Consistently Favorable Safety & Tolerability Profile in Toddlers
Study Results of VIASKIN® Peanut Patch Consistently Demonstrate a Favorable Safety & Tolerability Profile in Toddlers1-4 Frequency of Treatment-Related Local Skin Reactions Are Further Reduced After 3 Years of Treatment • Consistent with other studies5, local Year 1† Year 2 Year 3 application site r
Slide 32: Accelerated Approval Pathway for VIASKIN Peanut Patch in Toddlers
Accelerated Approval Pathway for VIASKIN® Peanut Patch in Toddlers FDA Accelerated Approval Pathway to Licensure Designed to Facilitate & Expedite Promising Therapies Current FDA Guidance for Accelerated Approval (AA) FDA Confirms an AA Pathway for Includes 3 Qualifying Criteria: VIASKIN® Peanut Pat
Slide 33: Summary: VIASKIN Peanut – A Novel Drug-Device with Blockbuster Potential
SUMMARY: VIASKIN Peanut ─ A Novel Drug-Device with Blockbuster Potential High unmet need: medical consequence of accidental peanut consumption plus the ever-present impact on child and family’s quality of life Significant market size in BOTH indications Designed to meet outcome objectives of Immunot
Slide 34: Appendix
Appendix 1 ❖ VIASKIN Pipeline ❖ Manufacturing ❖ Intellectual Property DBV Technologies | Corporate Overview
Slide 35: Our Long-Term Vision is to Realize the Full Potential of the VIASKIN Patch Technology
Our Long-Term Vision is to Realize the Full Potential of the VIASKIN® Patch Technology Program Discovery Pre-clinical Phase 1 Phase 2 Phase 3 VIASKIN® Milk Patch (DBV135) – Cow’s Milk Allergy; MILES: Ages 2-17 years1 VIASKIN® Milk Patch (DBV135) – Eosinophilic Esophagitis; SMILEE: Ages 4-17 years2 A
Slide 36: Robust Intellectual Property Portfolio
Robust Intellectual Property Portfolio IP Protection in Various Countries, Encompassing: Core patch technology Condensation chamber Epicutaneous immunotherapy (EPIT) activates the immune system by allowing the Mechanism of action antigen to penetrate the upper layer of the epidermis (intact skin) Ma
Slide 37: Patch Manufacturing Capabilities
Patch Manufacturing Capabilities Integrated End-to-End Patch Manufacturing in Place Source Material Active Pharmaceutical Ingredient (API) Final Product Process Proprietary electrospray technology deposits a precise antigen dose without any adjuvant on a PET titanium backing film DBV Technologies |
Slide 38: Investor Relations and Contacts
Investor Relations Jonathan Neely, VP & Head of IR +1 848-388-4584 jonathan.neely@dbv-technologies.com Public Relations and Media Brett Whelan +1 848-350-7622 brett.whelan@dbv-technologies.com Partnering and Licensing generalinquiries@dbv-technologies.com Clinical Trial Participation clinicaltrials@